New Research on Inflammatory Breast Cancer

Author: Julie Matthews
November 15, 2011

Julie Matthews

Julie Matthews

Director of Content & Social Media at The Side-Out Foundation
Julie blogs about her personal experience with leukemia and life from a patient’s perspective.She also writes about Side-Out news and events.She is a race walker, a dog lover, and a dedicated explore.org #bearcam watcher.
Julie Matthews

Latest posts by Julie Matthews (see all)

Recently, Emanuel Petriocoin and Lance Liotta of George Mason University’s (GMU) Center for Applied Proteomics & Molecular Medicine (CAPMM) discovered that activation of the protein ALK (anaplastic lymphoma kinase) is associated with inflammatory breast cancer, a particularly aggressive form of the disease: “Mason Research Gives Hope to Women With Deadliest Breast Cancer”.

Although this study was not funded by The Side-Out Foundation, Side-Out is incredibly proud to be associated with CAPMM through research in related clinical trials for breast cancer (see the Side-Out Protocol and I-SPY 2). The findings of the inflammatory breast cancer study may be put to use in the second phase of the Side-Out Protocol.

Comment


  • This is indeed an exciting finding. Hopefully more study will validate the results and open ALK targeting as a new treatment option for appropriate IBC patients.

    It would be wonderful if this work would lead to an IBC specific arm of the 2nd phase of the Side-Out Protocol.


Advertisement